In another individual experiment (Fig. 5f), a consistent result was obtained for P-BS-CM1 → P-CM2 that exhibited no inhibitory effect on primary tumor, whereas AMD3100, a licensed CXCR4 antagonist, showed a dose-dependent anti-tumor activity. Here, CXCR4 is linked to neoplasm.